{"id":"NCT02763579","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)","officialTitle":"A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-07","primaryCompletion":"2018-04-24","completion":"2022-07-07","firstPosted":"2016-05-05","resultsPosted":"2019-06-13","lastUpdate":"2023-07-28"},"enrollment":503,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Carcinoma"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A, RO5541267, Tecentriq"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Atezolizumab + Carboplatin + Etoposide","type":"EXPERIMENTAL"},{"label":"Placebo + Carboplatin + Etoposide","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 \\[PD-L1\\] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.","primaryOutcome":{"measure":"Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population","timeFrame":"Baseline until PD or death, whichever occurs first (up to approximately 23 months)","effectByArm":[{"arm":"Placebo + Carboplatin + Etoposide","deltaMin":4.3,"sd":4.2},{"arm":"Atezolizumab + Carboplatin + Etoposide","deltaMin":5.2,"sd":4.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0170"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":114,"countries":["United States","Australia","Austria","Brazil","Chile","China","Czechia","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Poland","Russia","Serbia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["38280181","37931445","33439693","31959349","31466854","30280641"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":69,"n":196},"commonTop":["Anaemia","Alopecia","Nausea","Neutropenia","Neutrophil count decreased"]}}